Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00323895
NCT00323895
Completed
Phase 4

A Prospective, Randomized, Multi-Center Comparison of the CYPHER Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients With Intra-Des Restenosis

Cordis Corporation2 sites in 1 country320 target enrollmentStarted: March 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronary Artery Disease

Overview

Phase
Phase 4
Status
Completed
Enrollment
320
Locations
2
Primary Endpoint
In stent late loss.
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.

Detailed Description

This is a prospective, randomized study to be conducted at up to 33 sites in France with 3 groups of patients (1 group with intra-Taxus™ restenosis, 1 group with intra-Cypher™ restenosis and 1 control group with intra-BMS restenosis). All patients will have a repeat angiography at 9 to 12 months post-procedure and will be followed up to 12 months post-procedure.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia;
  • •Patient has an intra-DES (TAXUS™ OR CYPHER™) or intra-BMS restenosis of \>= 50% and \<100% (by QCA online of the MLD compared to the distal reference diameter) in a native coronary artery;
  • •Study target lesion must be located in a restenotic native coronary artery \>=2.25mm and \<=3.5mm in lumen diameter and \<=30mm in length by visual estimate and within a region up to 5mm to the proximal/distal stent edge;
  • •Study target lesion must have undergone coronary interventional treatment \>= 4 weeks previously. Patients with one ore more prior PTCA procedures at the target lesion are acceptable candidates.
  • •Study target lesion can not be located in a vessel containing another lesion requiring treatment. Lesions located in other vessels may be treated with percutaneous revascularization at the time of the procedure, BUT they must be successfully treated prior to the treatment of the study target lesion;
  • •Patient is candidate for a current percutaneous revascularisation technique;
  • •Patient is willing to comply with the specified follow-up evaluations (including angiographic follow-up);
  • •Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee;

Exclusion Criteria

  • •Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \>2 times normal within the preceding 72 hours and the CK enzymes remain above normal at the time of treatment;
  • •Has unstable angina classified as Braunwald A I-II-III;
  • •Unprotected left main coronary disease with ³50% stenosis;
  • •Significant (\>50%) stenoses of additional lesions proximal or distal to the target lesion(s) that might require revascularization or impede runoff;
  • •Target lesion is in an internal mammary artery, saphenous vein bypass graft or is located in the left main or is ostial;
  • •Stent implantation(s) is a non-elective, emergency procedure;
  • •Stent at the target restenosed lesion is neither TAXUS™ , CYPHER™ DES nor a BMS;
  • •Documented left ventricular ejection fraction \<=25%;
  • •Totally occluded vessel (TIMI 0 level).

Outcomes

Primary Outcomes

In stent late loss.

Time Frame: between 9 - 12 months

Secondary Outcomes

  • In-stent, in-segment, and in-lesion binary restenosis rate by QCA.(between 9 - 12 months)
  • In-lesion late loss as assessed by QCA.(between 9 - 12 months)
  • In-stent and in-lesion MLD, and percent diameter stenosis (%DS) as assessed by QCA.(between 9 - 12 months)
  • Target lesion revascularization (TLR).(30 days, 6 and 12 months)
  • Target vessel revascularization (TVR).(30 days, 6 and 12 months)
  • Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization.(30 days, 6 and 12 months)
  • Composite of Major Adverse Cardiac Events (MACE) defined as cardiac death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization.(30 days, 6 months and 12 months)

Investigators

Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials

Unknown
Phase 4
GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary OcclusionsCoronary Artery Disease
NCT00220558Società Italiana di Cardiologia Invasiva150
Completed
Phase 4
The REALITY Study - Head-to-Head Comparison Between Cypher and TaxusCoronary Artery Disease
NCT00235092Cordis Corporation1,335
Completed
Phase 4
Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial DiseasePeripheral Arterial Diseases
NCT00640770Cordis Corporation200
Completed
Phase 3
Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris PatientsIschemic Heart Disease
NCT00660478Evald Hoej Christiansen2,342
Completed
Not Applicable
The SOURT OUT IV TRIALIschemic Heart DiseaseCoronary AtherosclerosisPercutaneous Coronary Intervention
NCT00552877Odense University Hospital2,678